SCHEMBL4172382

SCHEMBL4172382

O=C(NCc1ccc(C(F)(F)F)cc1)c1ccc(S(=O)(=O)Nc2ncc(Cl)s2)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 5/20 0.67
SCN9A Q15858 3/20 0.46
PPARA Q07869 1/20 0.44
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 1/20 0.43
PPARD Q03181 1/20 0.43
AVPR2 P30518 1/20 0.43
GPR27 Q9NS67 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
BACE1 P56817 1/20 0.43
SORT1 Q99523 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ELANE P08246 1/20 0.41
NAMPT P43490 1/20 0.41
KDM1A O60341 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3159771 0.92 SCN3A (0.63) SCN3ASCN9APPARAMAPTMEN1
SCHEMBL4181496 0.89 SCN3A (0.60) SCN3ASCN9A
SCHEMBL4165250 0.88 SCN3A (0.68) SCN3ASCN9APPARAMAPTPPARD
SCHEMBL3260132 0.88 SCN3A (0.78) SCN3ASCN9APPARAMAPTMEN1
SCHEMBL3168090 0.86 SCN3A (0.65) SCN3ASCN9APPARAMAPTMEN1
SCHEMBL3162487 0.85 SCN3A (0.54) SCN3ASCN9A
SCHEMBL3159811 0.84 SCN3A (0.58) SCN3ASCN9A
SCHEMBL3163370 0.82 SCN3A (0.58) SCN3ASCN9AMAPTMEN1KMT2A
SCHEMBL3160217 0.82 SCN3A (0.67) SCN3ASCN9AMAPTMEN1KMT2A
SCHEMBL3161075 0.81 SCN3A (0.69) SCN3ASCN9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN9A 51/4885PPARA 2889/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN9A 51/4885PPARA 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.